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Abstract  24 
Background 25 
Circulating mesenchymal stem cells contribute to bone repair. Their incorporation in fracture 26 
callus is correlated to their bioavailability. In addition, Granulocyte-colony stimulating factor 27 
induces the release of vascular and mesenchymal progenitors. We hypothesized that this 28 
glycoprotein stimulates fracture healing, and analyzed the effects of its administration at low 29 
doses on bone healing.  30 
Methods 31 
27 adult male Sprague-Dawley rats underwent mid-femur osteotomy stabilized by centromedullar 32 
pinning. In a post (pre) operative group, rats were subcutaneously injected with 5µg/kg per day of 33 
Granulocyte-colony stimulating factor for 5 days after (before) surgery. In a control group, rats 34 
were injected with saline solution for 5 days immediately after surgery. A radiographic 35 
consolidation score was calculated. At day 35, femurs were studied histologically and underwent 36 
biomechanical tests.  37 
Findings 38 
5 weeks after surgery, mean radiographic scores were significantly higher in the Preop group 39 
7.75 (SD 0.42) and in the Postop group 7.67 (SD 0.52) than in the control group 6.75 (SD 0.69). 40 
Biomechanical tests showed femur stiffness to be more than three times higher in both the Preop 41 
109.24N/mm  (SD 51.86) and Postop groups 100.05N/mm (SD 60.24) than in control 42 
32.01N/mm (SD 15.78). Mean maximal failure force was twice as high in the Preop group 68.66 43 
N (SD 27.78) as in the control group 34.21N (SD 11.79). Histological results indicated a later 44 
consolidation process in control than in treated groups.  45 
Interpretation 46 
 3 
Granulocyte-colony stimulating factor injections strongly stimulated early femur fracture healing, 47 
indicating its potential utility in human clinical situations such as programmed osteotomy and 48 
fracture. 49 
Keywords : Three-point-bending test, Fracture healing, Granulocyte-colony stimulating factor, 50 
Circulating mesenchymal progenitor cells, Histology 51 
52 
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1. Introduction 53 
Fracture consolidation has long been considered a locoregional process involving mesenchymal 54 
progenitor cells derived from the tissues damaged by the trauma (local bone marrow, endosteum, 55 
bone tissue, periosteum, muscles). Following a series of cellular and molecular event cascades 56 
reminiscent of the embryonic stages of skeletal tissue formation, these cell precursors lead to the 57 
regeneration of the initially injured tissue. However, the 2000s saw the discovery of circulating 58 
osteoprogenitor cells (Kuznetsov et al., 2001; Labat et al., 2000), now known to contribute to the 59 
bone formation and repair process (Otsuru et al., 2007; Otsuru et al., 2008). In physiologic state, 60 
these cells represent 1 to 2% of circulating mononuclear cells in adults and nearly 10% in 61 
adolescents (Eghbali-Fatourechi et al., 2005). They increase in response to osteogenic 62 
requirements: in animals, during an ectopic osteogenesis process, they can transiently rise to 80% 63 
of circulating mononuclear cells (Otsuru et al., 2008). This cell pool can contribute up to 10% of 64 
the osteoblasts present in a fracture consolidation callus (Kumagai et al., 2008) and as much as 65 
50% of the osteocytes present in an ectopic bone regenerate (Otsuru et al., 2008). 66 
Intravenous injections of blood-derived osteoprogenitor cells stimulate fracture repair (Granero-67 
Molto et al., 2009; Wan et al., 2006). Their rate of incorporation into the callus increases 68 
proportionally to their serum bioavailability, until it reaches a plateau. Beyond this value, it 69 
remains stable regardless of increases in serum level (Granero-Molto et al., 2009). On the other 70 
hand, endogenous circulating osteoprogenitor cell bioavailability can be transiently boosted by 71 
the pharmacological use of bioactive molecules that trigger the mobilization of their medullary 72 
precursors, thereby favoring bone repair (Kumar et al., 2012; Matsumoto et al., 2008; Toupadakis 73 
et al., 2013). 74 
 75 
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G-CSF is a glycoprotein used in human therapeutics for its ability to mobilize medullary 76 
hematopoietic stem cells in systemic circulation. G-CSF also induces the mobilization of vascular 77 
stem cells (Minamino et al., 2005) and mesenchymal stem cells (Levesque et al., 2007; Tatsumi 78 
et al., 2008; Zhdanov et al., 2007), both of which are involved, to varying degrees, in skeletal 79 
tissue repair. In rats, there was a significant increase in CD34+ progenitor cells after five 80 
consecutive injections of G-CSF (Herrmann et al., 2018). These cells are capable of 81 
differentiating into osteogenic as well as vasculogenic lineages (Sidney et al., 2014).  82 
Surprisingly, few studies have been published on the use of G-CSF as a skeletal tissue repair or 83 
regeneration adjuvant (Kaygusuz et al., 2006; Wu et al., 2008). When administered topically, G-84 
CSF improves neovascularization and osteogenesis, which leads to regeneration of both critical-85 
size bone defects in a rabbit bone resection model (Ishida et al., 2010) and tendon graft in a 86 
ligamentoplasty model (Sasaki et al., 2008). When administered parenterally, G-CSF 87 
counterbalances the negative effects of NSAIDs on bone healing, probably by stimulating 88 
osteogenesis (Kaygusuz et al., 2006). In a rabbit femoral osteonecrosis model, the combined use 89 
of G-CSF and Stem Cell Factor cause increased osteoblast activity and improve local 90 
revascularization, leading to more effective regeneration of the necrotic bone tissue volume (Wu 91 
et al., 2008).  92 
To date, only two studies have focused on the effects of parenteral administration of G-CSF on 93 
fracture healing (Bozlar et al., 2005; Herrmann et al., 2018), both finding that G-CSF accelerated 94 
bone repair in rats. However, the doses used in these studies were respectively 2.5 (Bozlar et al., 95 
2005) and 5 times higher (Herrmann et al., 2018) than the recommended dose in human clinical 96 
practice with healthy subjects. In fact, for donors providing peripheral blood stem cells for 97 
recipients of hematopoietic stem cell transplants, recombinant human G-CSF is generally 98 
recommended at a dose of 10µg/kg per day. Even at this dose, side effects are observed, although 99 
 6 
when the dose is reduced, the side effects decrease (Lambertini et al., 2014). Furthermore, Bozlar 100 
et al. (2005) and Herrmann et al. (2018) chose to work only on emergency clinical applications 101 
(e.g fractures, large defects) and did not consider programmed clinical applications (e.g bone 102 
lengthening, tumor removal). 103 
In this work, from a perspective of the eventual therapeutic use of GCSF in humans, we 104 
investigated the effects of parenteral administration of a 5µg/kg per day dose of G-CSF on 105 
fracture consolidation in rats. We also investigated G-CSF administration pre-surgery vs G-CSF 106 
administration post-surgery. Pre-surgery administration mirrors the human clinical situation of a 107 
programmed osteotomy, and post-surgery administration mirrors a fracture situation.  108 
 109 
110 
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 Materials and Methods 111 
Twenty-seven male Sprague Dawley rats (OFA), weighing 500g and twelve weeks old at time of 112 
surgery were used in the experiment. The animals were fed a standard diet ad libitum. They were 113 
housed singly in cages in temperature-controlled rooms (22°C) having a 12h light cycle. All 114 
animal protocols were approved by the University of Aix-Marseille institutional animal care and 115 
use committee and the French research ministry (authorization number 02572.02), and performed 116 
in the conventional animal house of Marseille Medical Faculty (France). 117 
 118 
2.1 Surgical protocol 119 
The surgical model consisted of right femur mid-diaphyseal osteotomy, immediately 120 
osteosynthesized by centromedullary pinning. Under general anesthesia consisting of 121 
intraperitoneal Ketamine 75 mg/kg and Medetomidine 0.15 mg/kg and under strictly aseptic 122 
conditions, the right femur was exposed via a lateral subperiosteal approach. Medial-diaphyseal 123 
osteotomy was performed using piezotome. Retrograde centromedullary pinning (2 mm diameter 124 
Kirschner wires) was performed by lateral parapatellar arthrotomy. The muscular fascia was 125 
closed with separated resorbable stitches and the skin with slow-absorption continuous stitches. 126 
Postoperative analgesia and prophylactic antibiotic therapy consisted of an injection of 127 
Buprenorphine 0.05 mg/kg and subcutaneous Baytril 10 mg/kg peroperatively, then once per day 128 
for 3 days. Rats were followed weekly by radio to check that they were healthy. 129 
 130 
2.2 Experimental groups 131 
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Rats were randomized to one of three distinct pharmacological procedures. The "Postoperative" 132 
group (Postop) with 9 rats were injected subcutaneously with 5µg/kg per day of G-CSF 133 
(FILGRASTIM) for 5 days starting from surgery. The "Preoperative" group (Preop) with 9 rats 134 
received identical G-CSF injections for 5 days preoperatively. In the Control group, 9 rats were 135 
injected subcutaneously for 5 days with a saline solution, starting immediately after surgery.  136 
One rat died in the control group upon induction of anesthesia. One rat died in the Postop group 137 
being found dead one day after surgery. One rat in the Preop group was sacrificed three days after 138 
surgery due to splitting of the scar tissue. No locoregional infections or other complications were 139 
observed in the other animals. After 35 days of consolidation, the animals were sacrificed by 140 
intraperitoneal lethal injections of Sodium Pentobarbital 100 mg/kg.  141 
 142 
2.3 Radiographic analysis 143 
X-rays of the femurs subjected to surgery were taken immediately postoperatively, then at days 7, 144 
21 under general anesthesia and at day 35 after the sacrifice. A radiographic consolidation score 145 
(An et al., 1999) was calculated from the analysis of the X-rays by two orthopedic surgeons not 146 
involved in the study (Table 1) and who analyzed independently each x-ray according to the 147 
radiographic scoring system for fracture healing (An et al., 1999). The final score assigned to 148 
each x-ray was the mean of the scores of the two surgeons. 149 
 150 
 151 
Table 1: Radiographic scoring system for fracture healing (An et al., 1999) . 152 
CATEGORY SCORE 
Periosteal reaction  
 9 
• Full (across the defect) 3 
• Moderate 2 
• Mild 1 
• None 0 
Bone union  
• Union 3 
• Moderate bridge (> 50%) 2 
• Mild Bridge (< 50%) 1 
• Non-union 0 
Remodeling  
• Full remodeling cortex 2 
• Intramedullary canal 1 
• No remodeling 0 
Maximum total score 8 
 153 
2.4 Mechanical analysis 154 
Femurs subjected to surgery (6 femurs from control group, 6 femurs from Preop group and 6 155 
from Postop group) and healthy contralateral femurs (6 femurs from control group, 6 femurs from 156 
Preop group and 6 from Postop group) underwent destructive mechanical tests. The fixation pin 157 
and soft tissue were completely removed before tests.  158 
The fresh material was frozen and stored at -20°C, which does not alter the structure or properties 159 
of bone. The samples were slowly thawed at room temperature before preparation and 160 
mechanically tested under three-point-bending (Turner et al., 1993) on a testing device (MTS 161 
Instron 5566A, INSTRON© Elancourt, France, 1000N load with an accuracy of 0.19%). We 162 
used preconditioning at 1N and subsequently imposed a speed of 0.5mm per min. 163 
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Force/displacement curves were obtained. Failure force and stiffness of the fracture site were 164 
analyzed. 165 
 166 
2.5 Histological analysis 167 
Six femurs subjected to surgery underwent histological analysis after 35 days of consolidation (2 168 
from control group, 2 from Postop group, 2 from Preop group). The fixation pin was removed 169 
and the fracture site was isolated from the femur and fixed in 4% formaldehyde (Merk Millipore) 170 
in 0.01M phosphate buffer saline (Sigma-Aldrich) at pH 7.4 for one week. Following fixation, 171 
tissue samples were washed with deionized water and were dehydrated through an ethanol 172 
gradient of 60%, 80%, 95%, 100% ethanol, each step lasting 48 hours. Samples were cleared in 173 
methylcyclohexan (VWR international) for 48h before infiltration and embedding in Methyl 174 
methacrylate (MMA) resin (VWR international). Samples then underwent polymerization in a 175 
28°C water bath for 3 days. 176 
After trimming of the blocks, 5µm thick longitudinal sections were obtained using a microtome 177 
(Leica© RM 2265, Wetzlar, Germany) equipped with a D-profile tungsten-carbide knife. The 178 
sections were transferred to Superfrost Plus slides and stretched with 70% ethanol. Slides were 179 
covered with a plastic film, pressed and dried for 2 days. Before staining, MMA was removed 180 
from the sections by immersion in three changes of 2-methoxyethylacetate (Merk Millipore) for 181 
20min each, one change of ethanol 70 for 5min, one change of ethanol 40 for 5min, and then 182 
rehydrated in two deionized water baths. The sections were stained with toluidine blue and Von 183 
Kossa. They were dehydrated and mounted using a resinous mounting medium (Entellan, Merk 184 
Millipore). 185 
 186 
2.6 Statistical analyses 187 
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Due to the small size of the groups, we chose to use nonparametric tests. The nonparametric 188 
Kruskal-Wallis test was used to compare consolidation scores for the three groups (control, 189 
Preop, Postop) at each time point (J7, J21, J35). This same test was used to compare stiffness and 190 
failure force values for the three groups, both for the contralateral femurs and for the femurs 191 
subjected to surgery. The significance level was set at p<0.05. For the multiple comparisons, we 192 
used the Conover-Iman test with a Bonferroni correction. Statistical analysis was performed 193 
using XLSTAT software.  194 
 195 
2. Results 196 
3.1 Radiographic results 197 
Radiographic consolidation scores for all time points are presented in table 2. In the peripheral 198 
callus, asymmetrically distributed around the fracture site, signs of mineralization were visible 199 
from 7 days after surgery. At days 7 and 21, a significant difference was observed between the 200 
control group and the Postop group alone (p = 0.001 at day 7; p = 0.001 at day 21). At day 35, we 201 
observed a significant difference between the control group and the Preop group (p = 0.008) as 202 
well as between the control group and the Postop group (p = 0.013). At this date, the osteotomy 203 
site remained visible on all femurs, pointing to incomplete remodeling. At each time point, the 204 
difference between the two treated groups was not significant (p = 0.094 at day 7; p = 0.046 at 205 
day 21; p = 0.806 at day 35). 206 
 207 
Table 2 : Radiographic score 208 
 Control group Preop group Postop group 
 12 
D + 7 postop 0.75 (0.27) 1.50 (0.84)  2.33 (1.13) * 
D + 21 post op 3.83 (0.82) 4.83 (0.75) 5.75 (0.82) * 
D + 35 postop 6.75 (0.69) 7.75 (0.42) * 7.67 (0.52) * 
Values are Mean (SD). D: day of surgery. * Significant by comparison with the control group. 209 
 210 
3.2 Mechanical results 211 
5 weeks after surgery, force/displacement curves were obtained for 18 healed femurs from the 212 
three experimental groups and for 18 control femurs obtained from their contralateral femurs.   213 
Although the femurs systematically fractured at the level of the bony callus during the 3-point 214 
bending tests, two types of failure profile were observed. The control group femurs experienced 215 
ductile failure, while the preop and postop groups femurs experienced brittle failure, like the 216 
contralateral group femurs (Figure 1). The contralateral femurs did not display any significant 217 
difference in mean stiffness (p = 0.24) or in maximum failure force (p = 0.17), irrespective of 218 
origin (control, Preop and Postop). Comparing the 3 experimental groups via the Kruskall-Wallis 219 
test, we found a significant difference in stiffness (p = 0.011) and maximal failure force (p = 220 
0.024). Concerning stiffness, the multiple comparisons showed that the control group 221 
significantly differed both from the Preop group (p= 0.002) and from the Postop group (p = 222 
0.003). Mean callus stiffness was slightly more than three times higher in the Preop 109.24 223 
N/mm (SD 51.86) and in the Postop groups 100.05 N/mm (SD 60.24) than in the control group 224 
32.01 N/mm (SD 15.78). 225 
Concerning maximal failure force, the multiple comparisons showed that the control group 226 
significantly differed from the Preop group (p= 0.004) but no difference from the Postop group 227 
was observed (p = 0.053). Mean maximal failure force was twice as high in the Preop group 228 
68.66 N (SD 27.78) as in the control group 34.21N (SD 11.79). No significant difference was 229 
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observed between Preop and Postop groups neither for stiffness (p = 0.884) nor for failure force 230 
(p = 0.217).  231 
 232 
 233 
Table 3. Mechanical results. 234 
 235 
 Contralateral Femurs Operated femurs 
 Stiffness (N/mm) 
 
Max failure force 
(N) 
Stiffness (N/mm) 
 
Max failure force 
(N) 
Control Group 327.03 (16.71) 191.38 (27.96) 32.01 (15.78) 34.21 (11.79) 
Preop Group 380.75 (123.20) 169.53 (28.65) 109.24 (51.86)* 68.66 (27.78) * 
Postop Group 386.19 (61.65) 169.14 (19.20) 100.05 (60.24) * 51.65 (16.75) 
Values are Mean (SD). * Significant by comparison with the control group. 236 
 237 
3.3 Histological results 238 
In the control group, a fibrous tissue joined the two cortices, while incomplete bony union was 239 
observed in the periosteal callus (Fig 2a). The latter was composed of centrally located 240 
uncalcified and calcified cartilage adjacent to newly woven bone, indicating endochondral 241 
ossification (Fig 3a). At the periphery, the periosteal callus consisted of woven and lamellar bone 242 
(Fig 2a). 243 
No difference was observed between the Preop and the Postop G-CSF-treated groups. Neither of 244 
the groups showed any evidence of endochondral ossification. There was complete bony union. 245 
The osteotomy gap was filled with anastomosed bone trabeculae in the periosteal region of the 246 
callus (Figs 2b and 2c) as well as between the cortices (Fig 3b). In the internal and periosteal 247 
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calluses, signs of bone formation and bone resorption indicated that remodeling of regenerated 248 
bone was occurring. Bone trabeculae showed on their surface osteoid tissue apposed to rows of 249 
osteoblasts and osteoclasts that resorbed bone (Fig 4). 250 
 251 
3. Discussion and conclusion 252 
The concomitant mobilization of angiogenic (Minamino et al., 2005) and mesenchymal stem 253 
cells (Wan et al., 2006; Levesque et al., 2007; Tatsumi et al., 2008) by G-CSF suggests its 254 
potential contribution to skeletal tissue repair. The purpose of this study was to evaluate the effect 255 
of low doses of G-CSF on the consolidation processes in fractures treated by open surgery, 256 
mirroring two human clinical situations: programmed osteotomy (Preop group) and fracture 257 
(Postop group). Our study showed that a 5µg/kg per day dose is sufficient to stimulate fracture 258 
repair processes. Five weeks after surgery, femurs from both treatment groups showed 259 
stimulation of osteotomy site consolidation stemming from systemic G-CSF administration. The 260 
efficacy of G-CSF in improving bone repair process was previously demonstrated at higher doses 261 
in rats, by Herrmann et al. (2018) and Bozlar et al. (2005). In the latter study, in a rat model of 262 
tibia fracture, the authors observed a 10-fold increase in callus mechanical strength three weeks 263 
after surgery in animals treated with a 25µg/kg per day G-CSF injection. In our study, maximal 264 
failure force was twice as high in the Preop group as in the control group, and callus stiffness 265 
slightly more than tripled in both G-CSF groups compared to control. Since our mean failure 266 
force values obtained on healthy bone were similar to those reported in the literature for rats of 267 
the same genetic origin, age and sex (Utvåg et al., 1998a; Utvåg et al., 1998b, Utvåg et al., 2001), 268 
methodological issues can be excluded. The difference in mechanical values is probably related 269 
to the dose of G-CSF administered. Moreover, we did not observe any impairment of 270 
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biomechanical behavior in the femurs not subjected to surgery, even though prolonged medullary 271 
progenitor cell mobilization is known to lead to deterioration of bone tissue (Wu et al., 2008; 272 
Toupadakis et al., 2012). This result is not surprising in view of the short period of injection with 273 
G-CSF. 274 
Histological analysis corroborated the biomechanical results. In G-CSF treated animals, we 275 
observed the complete replacement of endochondral cartilage by bone trabeculae, evidence that 276 
the process of remodeling is underway. In the control group animals, however, we observed the 277 
persistence of cartilaginous tissue in the process of ossification, which indicates a later 278 
consolidation process than in the treated group. The difference between control group and treated 279 
groups in terms of tissue type within the callus probably explains why ductile failure was 280 
observed in the control animals’ bone and brittle failure in animals treated with G-CSF. 281 
In human clinical practice, G-CSF is administered both to patients with chronic neutropenia or 282 
cancer and to donors providing peripheral blood stem cells for recipients of hematopoietic stem 283 
cell transplants. In healthy donors, G-CSF is recommended at the dose of 10 µg/kg administered 284 
once daily, and although well tolerated, it induces side effects. In a large prospective study, 285 
Pulsipher et al. (2014) reported that some rare life-threatening events occurred after G-CSF 286 
administration in healthy donors and that no fatalities occurred. In addition, treated donors 287 
showed no evidence of increased risk for cancer, autoimmune illness and stroke. The most 288 
common adverse event associated with G-CSF administration in healthy donors is bone and 289 
musculoskeletal pain (Lambertini et al., 2014; Tigue et al., 2007). To prevent and treat this pain, 290 
nonsteroidal anti-inflammatory agents are commonly used as a first-line treatment, and dose 291 
reductions are considered as second-line therapy (Lambertini et al., 2014). Thus, with a view to 292 
using G-CSF treatment as a fracture repair adjuvant in humans, we chose to test a low dose of G-293 
CSF. 294 
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Our therapeutic approach, derived from regenerative medicine, is founded on the well- 295 
documented contribution from circulating progenitor cells to many tissue repair processes. 296 
Stimulation of bone repair processes is related to the increased bioavailability of circulating 297 
vascular and mesenchymal progenitor cells at the neo-osteogenesis site (Kumar et al., 2012; 298 
Matsumoto et al., 2008; Toupadakis et al., 2013; Pignolo et al., 2011). Their incorporation into 299 
the skeletal tissue repair site contributes to many steps in the cascade of cellular and molecular 300 
events of the endochondral osteogenesis processes. During initial stages, these cells modulate the 301 
local and systemic inflammatory response (Iguchi et al., 1991) and induce local emission of 302 
cytokines such as BMP-2 that initiate bone tissue repair processes (Granero-Molto et al., 2009). 303 
During a later phase, vascular invasion of the cartilage matrix is promoted by angiogenesis and 304 
vasculogenesis mechanisms. The latter are supported by the influx and proliferation of circulating 305 
angiogenic progenitor cells of medullary origin (Matsumoto et al., 2008; Minamino et al., 2005), 306 
which depend on their serum level (Lee et al., 2008). This neoangiogenesis allows the influx of 307 
circulating osteogenic progenitor cells, which are incorporated into the callus undergoing 308 
ossification. Their incorporation is also dependent upon their serum level (Granero-Molto et al., 309 
2009). Now, according to Herrmann et al. (2016), the bioavailability of vascular and osteogenic 310 
progenitor cells such as CD34+ significantly increased after five consecutive injections of G-CSF 311 
in rats. In addition, in patients with femoral and tibial nonunion, it has been observed 312 
radiographically that fracture healing improved when G-CSF-mobilized CD34+ cells were 313 
transplanted to non-union sites (Kuroda et al., 2014). Thus, the stimulation of fracture repair by 314 
systemically administered G-CSF observed in our study could result from G-CSF-induced 315 
medullary mobilization of vascular and mesenchymal progenitor cells in the vascular 316 
compartment, leading to increased incorporation at the tissue repair site. Nevertheless, the 317 
possibility that G-CSF improves consolidation by other mechanisms cannot be ruled out. Froberg 318 
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et al. (1999) showed that G-CSF induces an increase in blood markers of bone formation such as 319 
osteocalcin and bone-specific alkaline phosphatase, which suggests that G-CSF stimulates 320 
osteoblastic activity. In addition, the effects of G-CSF could also be related to an increase in 321 
some cytokines. In an in vitro model, Kaygusuz et al. (2006) showed that G-CSF, while raising 322 
the TGFβ1, has a positive effect on fracture healing and Czekanska et al. (2014) that stimulation 323 
of mesenchymal stem cells by G-CSF results in an upregulation of mRNA expression of BMP2, 324 
which is involved in bone formation.  325 
The rate of incorporation of circulating progenitor cells into the fracture callus is time- and dose-326 
dependent (Granero-Molto et al., 2009). These cells can interact both qualitatively and 327 
quantitatively at various stages and times in the osteogenesis process (Iguchi et al., 1991; Lee et 328 
al., 2008). We therefore modulated the bioavailability peak of circulating progenitor cells in order 329 
to make it overlap with various times and stages in the bone consolidation process.  330 
We compared two different chronological sequences, one in which the adjuvant treatment 331 
preceded the surgical procedure and one in which it followed the surgery. Five weeks after 332 
surgery, no significant difference was observed between the Preop and the Postop groups, neither 333 
in callus mechanical behavior nor in the biological structure of the regenerated bone at the 334 
fracture site. However, mechanical tests are structural analysis, so we have no information about 335 
the callus undergoing ossification and its microstructure. Yet the mechanical characteristics of the 336 
callus are governed by its morphology, volume and material characteristics, in particular its 337 
degree of mineralization and remodeling. Moreover, only the consolidation score of the Postop 338 
group differs from that of the control group at days 7 and 21, indicating potential differences in 339 
degree of mineralization between the two treated groups. This difference in consolidation score 340 
disappears at day 35. This suggests that, despite the similar radiological profile and mechanical 341 
behavior of the explants from the two treated groups observed five weeks after surgery, the 342 
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pharmacological effect of G-CSF may have stimulated different stages in the endochondral 343 
ossification process.  344 
During skeletal tissue regeneration, systemic cell mechanisms participate in tissue repair. 345 
Medullary mesenchymal and vascular progenitor cells are mobilized in systemic circulation, then 346 
captured at the tissue repair site, where they participate in the various stages of the cellular and 347 
molecular events leading to the restoration of injured tissue (Kuroda et al., 2014). G-CSF 348 
increases the bioavailability of these circulating progenitor cells. However, we measured neither 349 
the kinetics, nor the intensity of blood mobilization of progenitor cells. The correlation between 350 
the pharmacological increase in progenitor cell bioavailability and fracture repair stages will be 351 
studied in future experimental work. It would be of interest to reevaluate treatment duration and 352 
starting time for G-CSF injections relative to the biological phases of the endochondral 353 
osteogenesis process. Finally, the stimulation mediated by G-CSF can be considered either in 354 
terms of consolidation speed and functional recovery, or in terms of final fracture site strength. In 355 
the present study, we chose to study the radiographical, mechanical and histological 356 
characteristics of the callus before completion of consolidation and bone remodeling. It would be 357 
interesting to follow consolidation callus kinetics to completion. This would reveal whether the 358 
final consolidation product is obtained earlier, and whether it is mechanically more efficient in 359 
the G-CSF treated groups than in the control group after callus remodeling. Despite its 360 
limitations, this study demonstrates that a low-dose, short-term systemic G-CSF adjuvant 361 
treatment stimulates fracture repair, indicating its potential utility in human clinical situations 362 
such as programmed osteotomy and fracture. The therapeutic modalities of this emerging 363 
"regenerative medicine" strategy remain to be determined. 364 
 365 
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Figure legends 479 
 480 
Fig 1. Examples of force/displacement curves for femurs from the control, preop, postop 481 
groups and for contralateral femurs.  482 
 483 
Fig 2. Low magnification of the fracture calluses 5 weeks after the osteotomy in control (a), 484 
preop (b) and postop group (c). Sections were stained with Von Kossa and counterstained with 485 
toluidine blue. (a) Note the fibrous tissue (*) between the cortices (C). Near the site of the 486 
osteotomy, the periosteal callus (P) is composed of bony and cartilaginous tissue. (b et c) Bony 487 
bridge (arrowheads) joins the fractured ends in the internal and in the periosteal callus regions. 488 
Scale bar 2mm. 489 
 490 
Fig 3: Micrograph of section stained with Von Kossa and counterstained with toluidine blue 491 
from the control group (a) and from the Postop group (b) 5 weeks after osteotomy. (a) Around the 492 
fracture gap, the reparative process occurs by endochondral ossification. New bone formation 493 
(arrow). Capillary invasion (*). Hypertrophic chondrocyte embedded in calcified cartilage 494 
(arrowhead). Uncalcified cartilage (UC). Scale bar 100µm. (b) A network of anastomosed 495 
trabeculae (arrows) is observed between the cortices (C). In this specimen, trabeculae are 496 
composed mainly of mature bone. Scale bar 500µm. 497 
 498 
Fig 4: Micrograph of section stained with toluidine blue from the postop group 5 weeks after 499 
osteotomy. On either side of bone trabeculae, the osteoclasts (arrowheads) and osteoblasts that 500 
deposit the osteoid (arrows) are observed. Scale bar 50µm. 501 
 502 
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